New study aims to unlock the secrets of a rising lung disease

NCT ID NCT07245407

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 4 times

Summary

This study follows 320 Chinese adults with non-cystic fibrosis bronchiectasis (a chronic lung condition causing cough and infections) and some healthy volunteers for 12 months. Researchers will collect lung function tests, blood samples, and imaging to identify biomarkers and disease patterns. The goal is to better understand the disease and pave the way for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to: If successful, this study could reveal key biological markers and disease subtypes, pointing toward more personalized treatments for bronchiectasis.
What could go wrong: This is an observational study, not a treatment trial. It will not directly test any therapy, and results may take years to influence clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

251 people

The number who actually took part.

Started

Oct 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Healthy controls will include at least 20 healthy participants aged 30 years or older, with no clinically significant lung disease or chronic lung disease. A total of up to 300 NCFBE patients (males and females aged 18 years or older) will be recruited and enrolled into the study. Patient numbers are mainly based on feasible situation. Approximately 30% of NCFBE patients in the study will be required to have had at least 2 exacerbations in the past 12 months. A subset of 60 NCFBE patients and 20 healthy participants is planned for an optional bronchoscopy assessment.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Healthy control cohort: · Age ≥30 years Bronchiectasis cohort: * Capable of giving signed informed consent. * Participant must be ≥18 years of age, at the time of signing the ICF. * Able to perform acceptable lung function testing according to ATS/ERS 2019 acceptability criteria. * Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center, and use electronic devices (e.g. FENO and spirometry). * Documented physician-diagnosed bronchiectasis: with a clinical history consistent with bronchiectasis (chronic cough and daily sputum production etc.) and having performed chest HRCT indicating bronchiectasis. * Remaining clinically stable upon recruitment. Patients with exacerbations are allowed to be enrolled into the study at least 4 weeks after the end of exacerbations. If a patient experiencing exacerbation and directly enters the exacerbation visit, the patient is required to come to the study site for baseline visit (after confirming that all inclusion/exclusion criteria are met) within 4 weeks /+ 3 days after the end of exacerbation Exclusion Criteria: Healthy control cohort: * Any respiratory diagnosis (asthma, COPD, bronchiectasis, pulmonary fibrosis or any other chronic respiratory condition requiring regular treatment). * Inflammatory conditions including rheumatoid arthritis, inflammatory bowel disease, any other connective tissue disease. * Active malignancy excluding non-melanoma skin cancer. * Antibiotic treatment for an acute respiratory tract infection in the previous 4 weeks or current sinusitis. * Any contraindication to study procedures including bronchoscopy. * Current smoking or smoking in the preceding 3 months. * Treatment with anti-coagulants. Bronchiectasis cohort: * Traction bronchiectasis associated with interstitial lung disease or other pulmonary disorders (e.g., pulmonary fibrosis and cystic fibrosis). * Primary diagnosis of another pulmonary condition, including COPD, asthma. Patients with a secondary diagnosis of these pulmonary diseases will be allowed to participate as long as bronchiectasis is considered by the investigator to be the primary diagnosis. * Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could: * Affect the safety of the participant throughout the study * Influence the findings of the study or the interpretation * Impede the participant's ability to complete the entire duration of study * The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation. * Active malignancy excluding non-melanoma skin cancer. * Participants is female who is pregnant or lactating or up to 6 weeks post-partum or 6 weeks cessation of breastfeeding. * The participant has an altered mental status at the time of informed consent. * History or current evidence of an upper or lower respiratory infection or symptoms(including common cold) within 2 weeks of baseline assessments * Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study center). * Terminal disease and/or organ failure or participants otherwise considered not appropriate for the study participation.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-cystic fibrosis bronchiectasis

Contacts and locations

Locations

Affiliated Hospital of Guangdong Medical University"

Zhanjiang, Guangdong, China
Anning First People's Hospital

Anning, Yunnan, China
Beijing Chaoyang Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, China
Beijing Hospital

Beijing, Beijing Municipality, China
Chengdu Fifth People's Hospital

Chengdu, Sichuan, China
Gansu Provincial Hospital

Lanzhou, Gansu, China
Guizhou Provincial People's Hospital

Guiyang, Guizhou, China
Henan Provincial People's Hospital

Zhengzhou, Henan, China
Huadong Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, China
Huzhou Central Hospital

Huzhou, Zhejing, China
Jiaxing First Hospital

Jiaxing, Zhejing, China
Jiaxing Second Hospital

Jiaxing, Zhejiang, China
Ningbo Fenghua District People's Hospital

Ningbo, Zhejiang, China
Peking University People's Hospital

Beijing, Beijing Municipality, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China
Shanghai Fifth People's Hospital

Shanghai, Shanghai Municipality, China
Shanghai General Hospital

Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China
Shanghai Tongji Hospital

Shanghai, Shanghai Municipality, China
Shenzhen People's Hospital

Shenzhen, Guangdong, China
Shiyan Taihe Hospital

Shiya, Hubei, China
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

Chengdu, Sichuan, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China
The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China
The First Affiliated Hospital of Kunming Medical University

Kunming, Yunnan, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China
The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Zhengzhou, China
The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Fujian Medical University

Quanzhou, Fujian, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China
The Second Hospital of Jilin University

Changchun, Jilin, China
Weifang People's Hospital

Weifang, Shandong, China
West China Hospital of Sichuan University

Chengdu, Sichuan, China
Xiangya Hospital of Central South University

Changsha, Hunan, China
Zhengzhou People's Hospital

Zhengzhou, Henan, China
Zhongshan Hospital Affiliated to FuDan University"

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.